Technology | Population Health | January 28, 2016

Boston Scientific and Accenture Develop Digital Health Solution for Chronic Cardiovascular Conditions

Care Pathway Transformation solution designed to help providers make better-informed decisions based on patient population insights

January 28, 2016 — Boston Scientific Corp. and Accenture have developed a cloud-based, data-driven digital health solution for hospitals to help improve patient outcomes and reduce costs to treat patients with chronic cardiovascular diseases.

The solution, known as Advantics Care Pathway Transformation, is designed to enable providers to make more proactive and informed decisions based on insights into the patient population. The goal ultimately is improving the care a patient experiences from hospital stay through post-discharge care and in-home support.

The Care Pathway Transformation solution uses the Accenture analytics insights platform, which provides actionable insights into care coordination and patient population health patterns, revealing opportunities to improve their consistency and efficiency. The solution will focus on three key measurements:

  • Pathway Analytics: how a patient moves through the hospital system, how long each step takes and whether a patient can be better served by a more efficient system;
  • Care Management: how patients are diagnosed, treated and monitored, by whom and how often, as well as their ongoing vital signs and risk analysis; and
  • Patient Engagement: how patients are educated, monitored and receive communication during their hospitalization and after discharge.

The solution has been tailored for insight into patients with heart failure, but the companies plan to expand it to additional disease states.

In developing this solution, both companies worked with two of the largest hospitals in Scandinavia — Karolinska University Hospital in Sweden and Tampere Heart Hospital in Finland — to assess the current state of care delivery for heart failure patients and identify opportunities for improvement at each hospital. Heart failure has been identified as one of the costliest disease states to manage — resulting in about 2 percent of healthcare spending and accounting for an average 11-day hospital stay in Europe.

"The collaboration with Boston Scientific and Accenture exposed significant opportunities to increase provider collaboration and improve the quality of care that patients experience when coming to our hospital," said Kari Niemelä, M.D., chief executive officer, Tampere Heart Hospital. "For example, we identified a 25 percent unnecessary heart failure readmissions rate, and therefore a definite need for better care coordination, supported by modern technology and processes that can decrease overall costs."

The two companies initially plan to make the Care Pathway Transformation solution available to hospitals in the United Kingdom and Scandinavia, and expect to pilot projects throughout Europe and the United States soon.

For more information: www.bostonscientific.com, www.accenture.com

Related Content

Arto System Shows Promise as Less-Invasive Therapy for Heart Failure Patients
News | Heart Failure| May 26, 2017
Recent outcomes from the MAVERIC clinical trial confirm earlier positive findings that MVRx’s Arto System safely and...
Sponsored Content | Videos | Cardiovascular Ultrasound| May 26, 2017
This video, provided in partnership with the American Society of Echocardiography (ASE), is titled "Intraoperative Tr
News | Enterprise Imaging| May 25, 2017
At the 2017 annual meeting of the Society for Imaging Informatics in Medicine (SIIM), June 1-3 in Pittsburgh, Konica...
Heart Failure Mortality Inversely Related to Wealth of Country
News | Heart Failure| May 24, 2017
Death in patients with heart failure is inversely related to the wealth of the country they live in, according to late...
Memorial Hospital of Gulfport used a McKesson cardiovascular information system (CVIS) to improve workflow efficiency

Memorial Hospital has increased efficiency using a single cardiovascular information management database. 

Sponsored Content | Case Study | Cardiac PACS| May 23, 2017
Located along Mississippi’s Gulf Coast, Memorial Hospital at Gulfport is a nonprofit, 445-bed facility originally est
News | Heart Failure| May 22, 2017
Serelaxin failed to meet the primary endpoints of the phase 3 RELAX-AHF-2 trial, according to late-breaking results...
Partners HealthCare and GE Healthcare Launch 10-year Collaboration on Artificial Intelligence
News | Artificial Intelligence| May 17, 2017
May 17, 2017 — Partners HealthCare and GE Healthcare announced a 10-year collaboration to rapidly develop, validate a
WiSE CRT System is a wireless cardiac resynchonization therapy device with no lead wires

The WiSE CRT System uses a tiny implant in the left ventricle to synchronize the heart, overcoming limitations of traditional Cardiac Resynchronization Therapy (CRT) in heart failure patients.

News | Heart Failure| May 12, 2017
May 12, 2017 – New study proves safety of novel, wireless pacing system, WiSE CRT (Wireless Stimulation Endocardially
Biotronik Announces FDA Approval of MultiPole Pacing
Technology | Cardiac Resynchronization Therapy Devices (CRT)| May 11, 2017
May 11, 2017 — Biotronik announced U.S.
Overlay Init